PMID- 30764058
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 3
IP  - 6
DP  - 2008 Nov
TI  - Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.
PG  - 671-690
LID - 10.1586/17446651.3.6.671 [doi]
AB  - Exenatide is the first in a novel class of drugs that mimics naturally occurring 
      glucagon-like peptide 1. In patients with Type 2 diabetes mellitus (T2DM), 
      control of both glycemia and bodyweight are important to minimize the risk of 
      diabetes complications. Exenatide improves glycemic control through 
      glucose-dependent insulin secretion, suppression of glucagon secretion, delaying 
      gastric emptying and suppressing appetite. Exenatide therapy significantly 
      reduced glycated hemoglobin (Hb(A1c)) and fasting and postprandial plasma glucose 
      when added to metformin and/or sulfonylureas, with an average weight loss of 2 
      kg. Furthermore, exenatide-treated patients sustained the reductions achieved in 
      Hb(A1c) at 12 weeks with a progressive reduction in bodyweight during 3-year 
      follow-up. Exenatide is generally well tolerated; nausea is the most common side 
      effect but significantly reduces over time and with gradual dose titration. 
      Hypoglycemia at a rate greater than placebo only occurred in combination with 
      sulfonylureas. Exenatide may enable patients with T2DM to improve glycemic 
      control while reducing the risk of hypoglycemia and provoking weight loss.
FAU - Tahrani, Abd A
AU  - Tahrani AA
AD  - a Division of Medical Sciences, University of Birmingham and Department of 
      Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK. 
      a.a.tahrani@bham.ac.uk.
FAU - Piya, Milan K
AU  - Piya MK
AD  - b Division of Medical Sciences, University of Birmingham and Department of 
      Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK. 
      m.k.piya@bham.ac.uk.
FAU - Barnett, Anthony H
AU  - Barnett AH
AD  - c Division of Medical Sciences, University of Birmingham and Department of 
      Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK. 
      anthony.barnett@heartofengland.nhs.uk.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
OTO - NOTNLM
OT  - GLP-1
OT  - Type 2 diabetes
OT  - exenatide
OT  - exenatide long-acting release
OT  - glucagon-like peptide-1
OT  - incretin
EDAT- 2008/11/01 00:00
MHDA- 2008/11/01 00:01
CRDT- 2019/02/16 06:00
PHST- 2019/02/16 06:00 [entrez]
PHST- 2008/11/01 00:00 [pubmed]
PHST- 2008/11/01 00:01 [medline]
AID - 10.1586/17446651.3.6.671 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2008 Nov;3(6):671-690. doi: 
      10.1586/17446651.3.6.671.